AstraZeneca (Sweden)

Browse company research profiles

Papers in the tracked journals with an author at AstraZeneca (Sweden): per year and category, where they are published, the institutions its researchers write with, and its most-cited papers. A paper counts as corporate when at least one of its authors is affiliated with an institution that OpenAlex classifies as a company; it counts once for each company among its authors' affiliations. Universities are the institutions OpenAlex classifies as education. Also as Markdown.

← Corporate research

Key findings#

From 2017 to 2026 (so far), authors at AstraZeneca (Sweden) took part in 38 papers in the tracked journals, most of them in health economics and policy (18), AI (12) and statistics (8).
5 of them were published in 2025, against 7 in 2017.
Since 2023, the institutions with the most of these papers were AstraZeneca (United Kingdom) (7), AstraZeneca (United States) (3) and University of Sheffield (3).
The journals publishing most of them were Nature Machine Intelligence (6), Metrika (2) and The European Journal of Health Economics (2).
The most-cited of them is “Interpretable bilinear attention network with domain adaptation improves drug–target prediction” (Nature Machine Intelligence, 2023), with 370 citations.
Since 2023, papers in the tracked journals cited 12 of its papers 68 times; 97% of those links came from papers with a university author and 0% from its own papers.
Its own papers since 2023 cite archived papers 23 times, 30% of them papers with a company author.
Across everything OpenAlex indexes, AstraZeneca (Sweden) has 14,062 works with 1,613,856 citations (h-index 405).
The tracked journals hold 34 of its 5,861 works in OpenAlex from 2017 to 2025 (0.6%).
Its main research topics in OpenAlex are Asthma and respiratory diseases (1,209), Computational Drug Discovery Methods (1,104) and Chronic Obstructive Pulmonary Disease (COPD) Research (1,058).
OpenAlex lists it under AstraZeneca (United Kingdom).

Papers per year#

20172026 (so far)

Papers per publication year and category
Category	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026 (so far)
Health Economics and Policy	6	0	4	2	1	0	2	0	2	1
AI	0	0	0	1	2	2	1	2	2	2
Statistics	1	1	0	0	1	2	1	0	1	1
All categories	7	1	4	3	4	4	4	2	5	4

Where the papers come from#

Journals with the most papers, since 2023
#	Journal	Papers
1	Nature Machine Intelligence	6
2	Metrika	2
3	The European Journal of Health Economics	2
4	PharmacoEconomics - Open	2
5	Machine Learning	1
6	PharmacoEconomics	1
7	BMC Medical Research Methodology	1

Institutions with the most papers, since 2023
#	Institution	Papers
1	AstraZeneca (United Kingdom)	7
2	AstraZeneca (United States)	3
3	University of Sheffield	3
4	Chalmers University of Technology	2
5	Karolinska Institutet	2
6	Novartis (Switzerland)	2
7	Recursion (United States)	2
8	University Medical Center Groningen	2
9	University of Gothenburg	2

Countries with the most papers, since 2023
#	Country	Papers
1	Sweden	15
2	United Kingdom	10
3	United States	4
4	Switzerland	2
5	Germany	2
6	Netherlands	2
7	Poland	2
8	Belgium	1
9	Canada	1
10	Indonesia	1

Keywords with the most papers, since 2023
#	Keyword	Papers
1	cost-effectiveness	4
2	denoising diffusion probabilistic models	2
3	drug discovery	2
4	incremental cost-effectiveness ratio	2
5	inverse protein folding	2
6	quality-adjusted life years	2
7	AI validation	1
8	EQ-5D-5L	1
9	Fisher information	1
10	HER2-negative breast cancer	1

Most-cited papers#

Most-cited papers since 2017
#	Citations	Per month	Title	Journal	Published	Authors
1	370	8.2	Interpretable bilinear attention network with domain adaptation improves drug–target prediction	Nature Machine Intelligence	2023-02-02	Peizhen Bai, Filip N. Miljković, Bino John et al.
2	235	3.0	Direct steering of de novo molecular generation with descriptor conditional recurrent neural networks	Nature Machine Intelligence	2020-05-18	Panagiotis-Christos Kotsias, Josep Arús‐Pous, Hongming Chen et al.
3	94	1.0	Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations	PharmacoEconomics	2019-05-18	Mario Ouwens, Pralay Mukhopadhyay, Yiduo Zhang et al.
4	59	1.1	Improving de novo molecular design with curriculum learning	Nature Machine Intelligence	2022-06-22	Jeff Guo, Vendy Fialková, Juan Diego Arango et al.
5	56	0.7	Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design	PharmacoEconomics	2019-09-30	Daniel Sugrue, Thomas T. Ward, Sukhvir Rai et al.
6	42	2.1	Data-driven federated learning in drug discovery with knowledge distillation	Nature Machine Intelligence	2025-03-05	Thierry Hanser, Ernst Ahlberg, Alexander Amberg et al.
7	38	1.2	Utilizing reinforcement learning for de novo drug design	Machine Learning	2024-04-08	Hampus Gummesson Svensson, Christian Tyrchan, Ola Engkvist et al.
8	32	1.3	A call for an industry-led initiative to critically assess machine learning for real-world drug discovery	Nature Machine Intelligence	2024-10-04	Cas Wognum, Jeremy R. Ash, Matteo Aldeghi et al.
9	17	0.2	Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006–2014	PharmacoEconomics - Open	2017-11-27	David Nathanson, Ugne Sabale, Jan W. Eriksson et al.
10	14	0.1	A three-dimensional anisotropic point process characterization for pharmaceutical coatings	Spatial Statistics	2017-06-20	Henrike Häbel, Tuomas Rajala, Mariagrazia Marucci et al.

Who cites its research#

Institutions whose papers cite it most, since 2023
#	Institution	Kind	Country	Links
1	Soochow University	University	China	6
2	Anhui University	University	China	3
3	Peking University	University	China	3
4	Bristol-Myers Squibb (United States)	Company	United States	3
5	Bristol-Myers Squibb (United Kingdom)	Company	United Kingdom	3
6	University of Sheffield	University	United Kingdom	3
7	Beijing Institute of Technology	University	China	2
8	University Medical Center Groningen	Healthcare	Netherlands	2
9	Central South University	University	China	2
10	Anhui Agricultural University	University	China	2

What its papers cite#

Institutions its papers cite most, since 2023
#	Institution	Kind	Country	Links
1	University of Toronto	University	Canada	3
2	University of Alberta	University	Canada	2
3	Bristol-Myers Squibb (United States)	Company	United States	2
4	University Medical Center Hamburg-Eppendorf	Healthcare	Germany	2
5	Bristol-Myers Squibb (United Kingdom)	Company	United Kingdom	2
6	Health Economics and Outcomes Research (United Kingdom)	Company	United Kingdom	2
7	Universidad de Navarra	University	Spain	2
8	University of Sheffield	University	United Kingdom	2
9	University of North Carolina at Charlotte	University	United States	1
10	AstraZeneca (United Kingdom)	Company	United Kingdom	1

Citation links inside the tracked journals; see the corporate citation network and industry–university links.

In OpenAlex#

AstraZeneca (Sweden) in OpenAlex
Item	Value
Type	Company
Location	Södertälje, Stockholm, Sweden
Part of	AstraZeneca (United Kingdom)
Units listed in OpenAlex	1
Works in OpenAlex	14,062
Citations	1,613,856
h-index	405
i10-index	21,157
2-year mean citedness	8.18
Website	www.astrazeneca.com
ROR	ror.org/04wwrrg31
OpenAlex	openalex.org/I4210143795

Main research topics (OpenAlex, all works)
#	Topic	Field	Works
1	Asthma and respiratory diseases	Medicine	1,209
2	Computational Drug Discovery Methods	Computer Science	1,104
3	Chronic Obstructive Pulmonary Disease (COPD) Research	Medicine	1,058
4	Pharmacogenetics and Drug Metabolism	Pharmacology, Toxicology and Pharmaceutics	903
5	Diabetes Treatment and Management	Medicine	770

Works and citations per year in OpenAlex, and its papers in the tracked journals
Year	Works in OpenAlex	Citations received	In the tracked journals	Share
2026 (so far)	434	41,907	4	0.9%
2025	704	51,426	5	0.7%
2024	729	51,369	2	0.3%
2023	685	47,500	4	0.6%
2022	644	45,449	4	0.6%
2021	721	44,846	4	0.6%
2020	673	37,666	3	0.4%
2019	632	29,863	4	0.6%
2018	577	25,842	1	0.2%
2017	496	24,152	7	1.4%

From OpenAlex's own record of the institution (CC0), read again monthly. Works and citations count everything OpenAlex indexes, not only the tracked journals; topics are OpenAlex's classification of those works.

Cite this page

Scholar4AI. (2026). AstraZeneca (Sweden). Journal and Conference Research Rankings. Retrieved November 5, 2026, from https://scholar4ai.com/companies/astrazeneca-sweden

@misc{scholar4ai-companies-astrazeneca-sweden,
  author = {{Scholar4AI}},
  title = {AstraZeneca (Sweden)},
  year = {2026},
  howpublished = {\url{https://scholar4ai.com/companies/astrazeneca-sweden}},
  urldate = {2026-11-05},
  note = {Journal and Conference Research Rankings; data from OpenAlex (CC0); licensed CC BY-NC 4.0}
}

Free to reuse for non-commercial purposes with attribution (CC BY-NC 4.0).